Incremental yield of genetic retesting in hypertrophic cardiomyopathy.
Abstract
Background
AND
Aims
Modern genetic testing in hypertrophic cardiomyopathy (HCM) includes newly described HCM-associated genes and full intronic regions of certain classic sarcomeric genes. This study evaluated genetic retesting in HCM patients with a prior negative test and identified predictors of a positive result to guide retesting.
Methods
This multicentre study included patients with HCM who previously had negative next-generation sequencing (NGS)-based genetic testing at four centres. Subjects were retested using an updated NGS-based HCM panel.
Results
Of 508 retested HCM patients (median age 70 years; 66.9% male; median maximal left ventricular wall thickness 18 mm; median interval from initial genetic test 6.6 years), 46 (9%) had 48 HCM-related variants: 14 in new HCM-associated genes, 3 in deep intronic MYBPC3 regions, 18 intermediate-effect variants, and 13 (8 reclassified) in classic HCM-associated genes. In multivariable analysis, the presence of late gadolinium enhancement (LGE) [odds ratio (OR) 3.52; 95% confidence interval (CI) 1.38-10.25], the Mayo HCM score (OR 1.46 per 1 point increase; 95% CI 1.08-2.01), and the Toronto HCM score (OR 1.18 per 1 point increase; 95% CI 1.08-1.30) were independent predictors of detecting HCM-related variants at retesting. The diagnostic yields in patients with LGE and a high Toronto score (≥13 points), and with LGE and a high Mayo score (≥4 points), were 80% and 50%, respectively.
Conclusions
In patients with HCM and prior negative genetic testing, retesting identified HCM-related variants in 9% of individuals, allowing counselling and risk stratification. Late gadolinium enhancement, combined with the Mayo and Toronto scores, may be used to guide which patients should be prioritized for genetic retesting.